A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Valemetostat (Primary)
Indications Adult T-cell leukaemia-lymphoma; B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
Sponsors Daiichi Sankyo Company

07 Feb 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2026.
12 Dec 2023 Results( At the primary trial cutoff (Dec 31, 2022), n=90) presented at the 65th American Society of Hematology Annual Meeting and Exposition, reporting primary clinical outcomes for the subgroup of pts in J101 with R/R B-NHLs, including DLBCL and FL.
12 Dec 2023 Primary Results(data cutoff (Dec 31, 2022, n=71 for pts in J101 with R/R T-NHLs ) assessing efficacy and safety Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphomas presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com